Update on Alzheimer drugs (galantamine)

Neurologist

Volumn 9, Issue 5, 2003, Pages 235-240

  Raskind, Murray A ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

Alzheimer disease; Cholinesterase inhibitor; Galantamine

Indexed keywords

CHOLINESTERASE INHIBITOR; GALANTAMINE; PLACEBO;

ALZHEIMER DISEASE; BEHAVIOR; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; META ANALYSIS; NAUSEA; PRIORITY JOURNAL; REVIEW; VOMITING;

ALZHEIMER DISEASE; ANIMALS; CHOLINESTERASE INHIBITORS; GALANTAMINE; HUMANS;

EID: 0141704173     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.nrl.0000087722.46430.c4     Document Type: Review

References (42)

1. Thomsen T, Kewitz H. Selective inhibition of human acetyl-cholinesterase by galanthamine in vitro and in vivo. Life Sci. 1990;46:1553-1558.
2. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet. 1976;2:1403.
3. Whitehouse PJ, Price DL, Struble RG, et al. Alzheimer's disease and senile dementia: loss of neurones in the basal forebrain. Science. 1982;215:1237-1239.
4. Thomsen T, Kaden B, Fischer JP, et al. Inhibition of acetylcholinesterase activity in human brain tissue and erythrocytes by galantamine, physostigmine and tacrine. Eur J Clin Chem Biochem. 1991;29:487-492.
5. Albuquerque EX, Alkondon M, Pereira EFR, et al. Properties of neuronal nicotinic acetylcholine receptors: pharmacological characterization and modulation of synaptic function. J Pharmacol Exp Ther. 1997;280:1117-1136.
6. Maelicke A, Albuquerque EX. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease. Eur J Pharmacol. 2000;393:165-170.
7. Whitehouse PJ, Martino AM, Antuono PG, et al. Nicotinic acetylcholine binding sites in Alzheimer's disease. Brain Res. 1986;371:146-151.
8. Perry E, Morris CM, Court JA, et al. Alteration in nicotine binding sites in Parkinson's disease, Lewy Body Dementia and Alzheimer's disease: possible index of early neuropathology. Neuroscience. 1995;64:385-395.
9. Sahakian BJ, Jones GMM. The effects of nicotine on attention, information processing, and working memory in patients with dementia of the Alzheimer type. In: Adlkofer F, Thruau K, eds. Effects of Nicotine on Biologic Systems. Basel: Birkhauser Verlag, 1991.
10. White HK, Levin ED. Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer's disease. Psychopharmacology. 1999;143:158-165.
11. Mihailova D, Yamboliev I, Zhivkova Z, et al. Pharmacokinetics of galantamine hydrobromide after single subcutaneous and oral dosage in humans. Pharmacology. 1989;39:50-58.
12. Bickel U, Thomsen T, Weber W, et al. Pharmacokinetics of galantamine in humans and corresponding cholinesterase inhibition. Clin Pharmacol Ther. 1991;50:420-428.
13. Bachus R, Bickel U, Thomsen T. The O-demethylation of the antidementia drug galantamine is catalysed by cytochrome P450 2D6. Pharmacogenetics. 1999;9:661-668.
14. Zhao Q, Lyver G, Lee P, et al. Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers. J Clin Pharmacol, submitted.
15. Chopin P, Briley M. Effects of four non-cholinergic cognitive enhancers in comparison with tacrine and galantamine on scopolamine-induced amnesia in rats. Psychopharmacology. 1992;106:26-30.
16. Sweeney JE, Bachmann ES, Coyle JT. Effects of different doses of galantamine, a long-acting acetylcholinesterase inhibitor on memory in mice. Psychopharmacology. 1990;102:191-200.
17. Woodruff-Pak DS, Vogel RW, Wenk GL. Galantamine: effect on nicotinic receptor binding, acetylcholinesterase inhibition and learning. PNAS. 2001;98:2089-2094.
18. Woodruff-Pak DS, Santos IS. Nicotinic modulation in an animal model of a form of associative learning impaired in Alzheimer's disease. Behav Brain Res. 2000;113:11-19.
19. Raskind MA, Peskind ER, Wessel T, Yuan W, and the Galantamine USA-1 Study Group. Galantamine in aD: a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology. 2000;54:2261-2268.
20. Wilcock GK, Lilienfeld S, Gaens E, on behalf of the Galantamine International-1 Study Group. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. BMJ. 2000;321:1-7.
21. Tariot PN, Solomon PR, Morris JC, et al. >and the Galantamine USA-10 Study Group. A 5-month, randomized placebo-controlled trial of galantamine in AD. Neurology. 2000;54:2269-2276.
22. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
23. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141:1356-1364.
24. Joffres C, Graham J, Rockwood K. Qualitative analysis of the clinician interview-based impression of change (Plus): methodological issues and implications for clinical research. Int Psychogeriatr. 2000;12:403-413.
25. Gelinas I, Gauthier L, McIntyre M, et al. Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. Am J Occup Ther. 1999;53:471-481.
26. Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Dis. 1997;11(Suppl 2):S33-S39.
27. Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology. 1997;48(Suppl 6):S10-S16.
28. Burns A, Rossor M, Hecker J, et al., and the International Donepezil Study Group. The effects of donepezil in Alzheimer's Disease: results from a multinational trial. Dement Geriatr Cogn Disord. 1999;10:237-244.
29. Morris JC, Cyrus PA, Orazem J, et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology. 1998;50:1222-1230.
30. Raskind MA, Sadowsky CH, Sigmund WR, et al. Effect of tacrine on language, praxis and noncognitive behavioral problems in Alzheimer's disease. Arch Neurology. 1997;54:836-840.
31. Skoog I, Nilsson L, Palmertz B, et al. A population-based study of dementia in 85-year-olds. N Engl J Med. 1993;328:153-158.
32. Snowdon DA, Greiner LH, Mortimer JA, et al. Brain infarction and the clinical expression of Alzheimer's disease. JAMA. 1997;277:813-817.
33. Kalaria RN, Ballard C. Overlap between pathology of Alzheimer's disease and vascular dementia. Alzheimer Dis Assoc Dis. 1999;13(Suppl 3):S115-S123.
34. Erkinjuntti T, Kurz A, Gauthier S, et al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet. 2002;359:1265-1266.
35. Roman GC, Tatemichi TK, Erkinjunti T, et al. Vascular dementia: diagnostic criteria for research studies: report of the NINDS-AIREN International Workshop. Neurology. 1993;43:250-260.
36. McKhann G, Drachman D, Folstein M, et al. Clinical Diagnosis of Alzheimer's disease: report of the NICDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984;34:939-944.
37. Caro JJ, Getsios D, Migliaccio-Walle K, et al. for the AHEAD Study Group. Assessment of health economics in Alzheimer's disease (AHEAD) based on need for full-time care. Neurology. 2001;57:964-971.
38. Getsios D, Caro JJ, Caro G, Ishak K, for the AHEAD Study Group. Assessment of health economics in Alzheimer's disease (AHEAD). Neurology. 2001;57:972-978.
39. Canadian Study of Health and Aging Working Group. Canadian Study of Health and Aging: study methods and prevalence of dementia. CMAJ. 1994;150:899-913.
40. Clipp EC, Moore MJ. Caregiver time use: an outcome measure in clinical trial research on Alzheimer's disease. Clin Pharmacol Ther. 1994;58:228-236.
41. Lilienfeld S, Papadopoulos G. Galantamine alleviates caregiver burden in Alzheimer's disease. Presented at the 14th Annual Meeting of the American Association for Geriatric Psychiatry, San Francisco, CA, February 2001.
42. Raskind MA, Truyen L. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Presented at the 15th Annual Meeting of the American Association for Geriatric Psychiatry, Orlando, FL, February 2002.